Shares of Aytu BioPharma Inc. (NASDAQ:AYTU – Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.19 and traded as high as $2.33. Aytu BioPharma shares last traded at $2.30, with a volume of 49,804 shares trading hands.
Analyst Ratings Changes
Several equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Zacks Research downgraded shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Finally, Ascendiant Capital Markets raised their target price on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Aytu BioPharma has an average rating of “Hold” and an average price target of $10.75.
Check Out Our Latest Stock Analysis on Aytu BioPharma
Aytu BioPharma Trading Up 4.1%
Aytu BioPharma (NASDAQ:AYTU – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The business had revenue of $12.41 million during the quarter, compared to analysts’ expectations of $12.05 million. On average, research analysts anticipate that Aytu BioPharma Inc. will post -0.73 earnings per share for the current year.
Hedge Funds Weigh In On Aytu BioPharma
Several hedge funds have recently added to or reduced their stakes in the stock. Daytona Street Capital LLC acquired a new stake in Aytu BioPharma during the 4th quarter worth $26,000. Rothschild Wealth LLC purchased a new position in shares of Aytu BioPharma during the fourth quarter worth about $52,000. Dimensional Fund Advisors LP acquired a new stake in shares of Aytu BioPharma during the third quarter worth about $58,000. Bellevue Asset Management LLC acquired a new stake in shares of Aytu BioPharma during the fourth quarter worth about $65,000. Finally, XTX Topco Ltd purchased a new stake in shares of Aytu BioPharma in the 4th quarter valued at about $67,000. 33.49% of the stock is currently owned by hedge funds and other institutional investors.
About Aytu BioPharma
Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.
Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.
Read More
- Five stocks we like better than Aytu BioPharma
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
